Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)

This study tests a combination of gemcitabine, cisplatin, nab-paclitaxel (chemotherapy drugs) plus cemiplimab (an immunotherapy drug) as treatment for locally advanced biliary tract cancer — which includes cancers of the bile ducts and gallbladder that cannot be surgically removed. **You may be eligible if...** - You have been diagnosed with biliary tract adenocarcinoma (intra- or extra-hepatic, or gallbladder) confirmed by biopsy - Your cancer is locally advanced and cannot be surgically removed but has not spread to distant organs - You have not yet received chemotherapy for this advanced disease - You are in reasonably good health and able to carry out daily activities **You may NOT be eligible if...** - Your cancer has spread to distant organs (metastatic disease) - You have already received chemotherapy for advanced disease - You have a history of autoimmune disease or are on immune-suppressing drugs - You have significant liver, kidney, or heart problems Talk to your doctor to see if this trial is right for you.